Marrow Therapeutics unveiled $173M to support a “Trojan Horse” delivery platform aimed at expanding access to therapies for sickle cell disease and beta thalassemia. The company’s premise is that improved manufacturing and dosing characteristics could reduce barriers associated with current gene therapies. The funding signals continued investor appetite for cell and gene delivery approaches that target practical deployment constraints, not only clinical efficacy. It also suggests that platform differentiation—how a therapy reaches the right cells and scales—remains a key theme in rare disease development. Next milestones will likely include expanding preclinical-to-clinical validation, demonstrating consistent delivery performance at scale, and providing comparability metrics against existing care standards.